Advanced searches left 3/3

Carcinomatosis Peritoneal - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Phase II Clinical trial of Sequential Treatment with Systemic Chemotherapy and Intraperitoneal Paclitaxel for Gastric and Gastroesophageal Junction Peritoneal Carcinomatosis - STOPGAP Trial

Background: According to Asian studies, normothermic intraperitoneal chemotherapy may have a long-term effect in patients with gastric peritoneal carcinomatosis. Patients with gastric/gynogyn junction adenocarcinoma PC are expected to live for one year after receiving a 1-year progression-free survival benefit of sequential systemic chemotherapy and paclitaxel NIPEC. Patients with histologically established gastric/GEJ adenocarcinoma with positive peritoneal cytology or PC will be eligible to participate after three months of research-based chemotherapy and with no evidence of visceral metastasis on restaging scans. Both before and after NIPEC's approval of the peritoneal cancer index will be determined by diagnostic laparoscopy. Patients with a PCI less than or equal to ten in whom complete cytoreduction is possible can request CRS with heated intraperitoneal chemotherapy.

Source link: https://europepmc.org/article/PPR/PPR591939


Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.

In nude mice, HCT-116 green fluorescent protein-expressing colon-cancer cells implanted intra-peritoneally found oral methioninase combined with oxaliplatinum plus 5-fluorouracil raises the survival of mice with peritoneal-carcinomatosis caused by intra-peritoneal bacillary cell transplantation of mice with peritoneal-carcinomatosis. Human colon-cancer cells from HCT-116-GFP human colon-cancer cells were transplanted intraperitoneally in athymic nude mice. Tumor tissues were also stained with hematoxylin and eosin, and eosin was also stained with hematoxylin and eosin. Results o-rMETase in combination with 5-FU + OXA significantly reduced peritoneal growth of the HCT-116 tumor in comparison to either the untreated control or the combination 5-FU and OXA group. Compared to the control or combination of 5-FU plus OXA treatments, the combination of 5-FU plus OXA and o-rMETase prolonged the mice with peritoneal carcinomatosis by a considerable length. Conclusions o-rMETase is a poster exhibit that shows the future clinical promise for improving patients with peritoneal metastasis of colon cancer when combined with first-line therapy of this recalcitrant disease.

Source link: https://europepmc.org/article/MED/36585181


Abdominal splenosis mimicking peritoneal carcinomatosis of ovarian cancer.

We discuss the clinical case of a 53-year-old woman who raised the possibility of recurrence of a mesonephric-like ovarian cancer. These radiological findings and the absence of significant rise in CA 125 levels prompted the radiologists to believe that abdominal splenism was related to abdominal splenosis. The Tc-labeled heat-denatured erythrocyte scintigraphy/ hybrid SPECT/CT was then performed for definitive diagnosis, revealing spleen remnants in the same locations as the nodules were discovered in the CT.

Source link: https://europepmc.org/article/MED/36593917


Can a morphological description of the peritoneal carcinomatosis in advanced ovarian cancer add prognostic information? Analysis of 1686 patients of the tumor bank ovarian cancer.

History Peritoneal carcinomatosis in ovarian cancer is common, and it is generally associated with a younger stage and poorer result. Peritoneal carcinomatosis' medical characteristics are varied, and their significance for surgical and long-term outcomes remains unclear. Methods We conducted a systematic review of all patients with documented intraoperative PC and a primary diagnosis of epithelial, tubal, or peritoneal cancer from January 2001 to September 2018. In addition, the effect of PC characteristics on OS and PFS was investigated. Results A total of 1686 patients with PC and primary epithelial ovarian cancer were included in the study. According to local PCs, elevated FIGO-stage, high-grade and serous tumors, as well as residual tumors were strongly linked with increased FIGO-stage, high-grade and serous tumors, as well as residual tumors. Comparing to dry PC, wet PCs were also significantly linked to diffuse localization and residual tumor. As compared to fine PCs, Coarse PC was significantly associated with residual tumors.

Source link: https://europepmc.org/article/MED/36620574


Late Recurrence of Pancreatic Solid Pseudopapillary Neoplasm With Peritoneal Carcinomatosis Treated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Case Report

Pancreatic solid pseudopapillary neoplasm is a rare malignant tumor that mostly affects young women. Peritoneal carcinomatosis in this setting is an even rarer disease, usually related to postoperative tumour rupture. We present a case of a 43-year-old woman who underwent splenopancreatectomy following the diagnosis of a pancreatic SPN. An implant with morphology compatible with pancreatic SPN was found during a Histological examination. Despite SPN's rapid growth, one must be aware of a potential recurrence several years after the primary resection, predominantly in patients with evidence of intraoperative tumour rupture.

Source link: https://europepmc.org/article/MED/PMC9728010


Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery for Colorectal Peritoneal Carcinomatosis Patients: A Review.

Colorectal peritoneal carcinomatosis is a rare disease of advanced malignancy, and it is usually associated with a poor prognosis. Hyperthermic intraperitoneal chemotherapy after complete cytoreductive surgery is a novel, cutting-regional therapy for colorectal cancer that is currently being used to treat peritoneal carcinomatosis. The present study seeks to explore the evidence-based literature on this therapy strategy in patients with colorectal cancer and to highlight the disorder's complications. The effectiveness of HIPEC for the treatment of CPC was reviewed in this paper; 16 studies were included in this collection. The overall median survival of patients in the HIPEC group was considerably higher than that in the non-HIPEC group. In conclusion, the present results reveal insufficient evidence regarding the beneficial effects of using HIPEC following CRS treatment. Because of this, further research is required to determine the benefits of HIPEC for CPC patients.

Source link: https://europepmc.org/article/MED/36523856

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions